Progressive membrane phospholipid changes in first episode schizophrenia with high field magnetic resonance spectroscopy

Psychiatry Research - Neuroimaging

Volumn 201, Issue 1, 2012, Pages 25-33

  Miller, Jodi ^a,b   Drost, Dick J ^a,b,c   Jensen, Eric ^e   Manchanda, Rahul ^a   Northcott, Sandra ^a   Neufeld, Richard W J ^a   Menon, Ravi ^a,c   Rajakumar, Nagalingam ^a   Pavlosky, William ^a,b   Densmore, Maria ^a,b   Schaefer, Betsy ^a   Williamson, Peter ^a,b,c,d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d WESTERN UNIVERSITY   (Canada)

^e MCLEAN HOSPITAL   (United States)

Author keywords

Chemical shift imaging; Longitudinal; Membrane metabolite; Phosphorus; Schizophrenia; Spectroscopy

Indexed keywords

GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; MEMBRANE PHOSPHOLIPID; PHOSPHORYLCHOLINE;

ADULT; ANTERIOR CINGULATE; ARTICLE; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCIPITAL CORTEX; PHOSPHOLIPID METABOLISM; PHOSPHOROUS MAGNETIC RESONANCE SPECTROSCOPY; POSTERIOR CINGULATE; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SUPERIOR TEMPORAL GYRUS; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CELL MEMBRANE; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEUROIMAGING; PHOSPHOLIPIDS; SCHIZOPHRENIA;

EID: 84862787635     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2011.06.017     Document Type: Article

References (47)

1. Alexander G.E., Crutcher M.D., DeLong M.R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Progress in Brain Research 1990, 85:119-146.
2. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1984, University of Iowa, Iowa City, IA.
3. Andreasen N.C. Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City, IA.
4. Batchelder W.H. Using multinomial processing tree models to measure cognitive deficits in clinical populations. Advances in Clinical Cognitive Science: Formal Modeling of Processes and Symptoms 2007, 19-50. American Psychological Association, Washington, DC. R.W.J. Neufeld (Ed.).
5. Bluhm R.L., Miller J., Lanius R.A., Osuch E.A., Boksman K., Neufeld R.W., Théberge J., Schaefer B., Williamson P. Spontaneous low-frequency fluctuations in the BOLD signal in schizophrenic patients: anomalies in the default network. Schizophrenia Bulletin 2007, 33(4):1004-1012.
6. Cox I.J., Puri B.K. In vivo MR spectroscopy in diagnosis and research of neuropsychiatric disorders. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2004, 70(4):357-360.
7. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biological Psychiatry 1994, 36(8):503-510.
8. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophrenia Bulletin 2008, 34(2):312-321.
9. Feinberg I. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence?. Journal of Psychiatric Research 1982, 17(4):319-334.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W., Benjamin L.S. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II) 1997, American Psychiatric Press, Inc., Washington, D.C.
11. Frith C. Functional imaging and cognitive abnormalities. Lancet 1995, 346(8975):615-620.
12. Frith C.D. The social brain?. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2007, 362(1480):671-678.
13. Fukuzako H., Fukuzako T., Takeuchi K., Ohbo Y., Ueyama K., Takigawa M., Fujimoto T. Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms. Progress in Neuro-Psychopharmacology & Biological Psychiatry 1996, 20(4):629-640.
14. Fukuzako H., Fukuzako T., Hashiguchi T., Kodama S., Takigawa M., Fujimoto T. Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. American Journal of Psychiatry 1999, 156(8):1205-1208.
15. Gattaz W.F., Kollisch M., Thuren T., Virtanen J.A., Kinnunen P.K. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biological Psychiatry 1987, 22(4):421-426.
16. Gattaz W.F., Schmitt A., Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia Research 1995, 16(1):1-6.
17. Glantz L.A., Gilmore J.H., Lieberman J.A., Jarskog L.F. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research 2006, 81(1):47-63.
18. Horrobin D.F., Glen A.I., Vaddadi K. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994, 13(3):195-207.
19. Huberty C.J., Petoskey M.D. Multivariate analysis of variance and covariance. Handbook of Applied Multivariate Statistics and Mathematical Modeling 2000, 183-208. Academic Press, New York. H. Tinsely, S. Brown (Eds.).
20. Hummel T.J., Sligo J. An empirical comparison of univariate and multivariate analysis of variance procedures. Psychological Bulletin 1971, 76:49-57.
21. 31P magnetic resonance spectroscopy study. Biological Psychiatry 2003, 54(4):491-494.
22. Jensen J.E., Al-Semann Y.M., Williamson P.C., Neufeld R.W., Menon R.S., Schaeffer B., Drost D.J. Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0Tesla. The British Journal of Psychiatry 2002, 180:39-44.
23. Jensen J.E., Drost D.J., Menon R.S, Williamson P.C In vivo brain (31)P-MRS: measuring the phospholipid resonances at 4Tesla from small voxels. NMR in Biomedicine 2002, 15(5):338-347.
24. 31P-MRS chemical shift imaging study at 4Tesla. The British Journal of Psychiatry 2004, 184:409-415.
25. 31P-MRS. Psychological Medicine 1995, 25(3):557-566.
26. Kirk R.E. Experimental Design: Procedures for the Behavioral Sciences 1995, Brooks/Cole, Pacific Grove, CA.
27. McClure R.K., Phillips I., Jazayerli R., Barnett A., Coppola R., Weinberger D.R. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Research: Neuroimaging 2006, 148(2-3):121-132.
28. Miller J., Williamson P., Jensen J.E, Machanda R., Menon R., Neufeld R., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Drost D.J. Longitudinal 4.0Tesla (31)P magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiatry Research: Neuroimaging 2009, 173(2):155-157.
29. Neufeld R.W. On the centrality and significance of stimulus-encoding deficit in schizophrenia. Schizophrenia Bulletin 2007, 33(4):982-993.
30. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Archives of General Psychiatry 1995, 52(12):998-1007.
31. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia. Schizophrenia Bulletin 1993, 19(1):35-53.
32. 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biological Psychiatry 1999, 45(6):687-693.
33. Premkumar P., Fannon D., Kuipers E., Simmons A., Frangou S., Kumari V. Emotional decision-making and its dissociable components in schizophrenia and schizoaffective disorder: a behavioural and MRI investigation. Neuropsychologia 2008, 46(7):2002-2012.
34. Rosen A., Hadzi-Pavlovic D., et al. The Life Skills Profile: a measure assessing function and disability in schizophrenia. Schizophrenia Bulletin 1989, 15(2):325-337.
35. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Archives of General Psychiatry 1997, 54(5):487-494.
36. Shen G.X., Boada F.E., Thulborn K.R. Dual-frequency, dual-quadrature, birdcage RF coil design with identical B1 pattern for sodium and proton imaging of the human brain at 1.5T. Magnetic Resonance in Medicine 1997, 38(5):717-725.
37. 31P-MR spectroscopy reveals frontal and thalamic metabolic abnormalities in schizophrenia. NeuroImage 2007, 35(2):729-737.
38. 31P-MR spectroscopy study. Schizophrenia Research 1994, 13(3):209-215.
39. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A., Thompson R.T. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Archives of General Psychiatry 1995, 52(5):399-406.
40. Stevens J. Applied Multivariate Statistics for the Social Sciences 1996, Lawrence Erlbaum Associates.
41. Théberge J., Bartha R., Drost D.J., Menon R.S., Malla A., Takhar J., Neufeld R.W., Rogers J., Pavlosky W., Schaeler B., Densmore M., Al-Semaan Y., Williamson P.C. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. The American Journal of Psychiatry 2002, 159(11):1944-1946.
42. Théberge J., Al-Semaan Y., Williamson P.C., Menon R.S., Neufeld R.W., Rajakumar N., Schaefer B., Densmore M., Drost D.J. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. The American Journal of Psychiatry 2003, 160(12):2231-2233.
43. Théberge J., Williamson K.E., Aoyama N., Drost D.J., Machanda R., Malla A.K., Northcott S., Menon R.S., Neufeld R.W., Rajakumar N., Pavlosky W., Densmore M., Schaefer B., Williamson P.C Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. The British Journal of Psychiatry 2007, 191:325-334.
44. 31P-magnetic resonance spectroscopic study. Biological Psychiatry 1999, 45(9):1221-1225.
45. Williamson P. Mind, Brain, and Schizophrenia 2006, Oxford University Press, Oxford.
46. 31P MRS. Phospholipid Spectrum Disorders in Psychiatry and Neurology 2003, 221-238. Marius Press, Carnforth, Lancashire. M. Peet, I. Glen, D.F. Horrobin (Eds.).
47. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry 2003, 64(6):663-667.